gemcitabine + eribulin

Gemcitabine + eribulin is a chemotherapy combination that has shown promising efficacy in various cancer types. This combination pairs two distinct mechanisms of action to potentially enhance anti-tumor effects. Eribulin is a non-taxane microtubule inhibitor that works by inhibiting the growth phase of microtubules without affecting the shortening phase and sequestering tubulin into nonproductive aggregates[8]. It specifically binds to the β-tubulin subunit, which may explain its ability to overcome taxane resistance conferred by β-tubulin mutations[6]. Gemcitabine is a nucleoside analog that mediates its antitumor effects by promoting apoptosis of malignant cells undergoing DNA synthesis[8]. After cellular uptake, gemcitabine is phosphorylated to form active metabolites (gemcitabine diphosphate and gemcitabine triphosphate) that compete with deoxycytidine triphosphate for incorporation into DNA, leading to "masked DNA chain termination," DNA fragmentation, and apoptotic cell death[8]. The combination of these two mechanisms—microtubule inhibition (eribulin) with nucleoside analog activity (gemcitabine)—has demonstrated synergistic effects in preclinical studies, particularly at low concentrations of both drugs[5][6]. This synergy appears to be most effective when eribulin is administered before gemcitabine[5]. Clinical trials have shown promising activity for this combination in various cancer types, including metastatic breast cancer (particularly HER2-negative and triple-negative subtypes), soft tissue sarcomas (especially liposarcoma and leiomyosarcoma), and urothelial bladder cancer[1][2][3][6][7]. ## Dosing The typical dosing regimen used in clinical trials includes: - Eribulin: 1.4 mg/m² intravenously on days 1 and 8 of a 21-day cycle - Gemcitabine: 1000 mg/m² intravenously on days 1 and 8 of a 21-day cycle Some studies have used slightly modified dosing, such as eribulin at 0.88 mg/m² with gemcitabine at 1000 mg/m²[6]. ## Efficacy The combination has demonstrated notable efficacy across several cancer types: - In HER2-negative metastatic breast cancer: Objective response rates of 38.9-50%, disease control rates of 85-96%, and median progression-free survival of 6.3-8.4 months[3][7] - In soft tissue sarcomas (liposarcoma and leiomyosarcoma): Progression-free survival rate at 12 weeks of 73%, objective response rate of 16.2%, and disease control rate of 78.4%[2] - In triple-negative breast cancer: Particularly active in this aggressive subtype[6] ## Safety Profile The combination generally shows a predictable and manageable safety profile. Common adverse events include myelosuppression (anemia, leukopenia, neutropenia, and thrombocytopenia), though events leading to discontinuation occur in less than 1% of patients[8]. The combination appears to cause less neurotoxicity than paclitaxel plus gemcitabine[3][7]. ## Development Status The combination is being actively studied in multiple cancer types, with several phase II trials completed or ongoing. It shows particular promise in metastatic breast cancer, soft tissue sarcomas, and urothelial bladder cancer that has spread to other parts of the body[1][2][3][6][7].

Brand names

HalavenGemzar

Other names

Gemcitabine combined with eribulinGemcitabine plus eribulin